Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VM-RHE-001
- Development stage
- Unknown
- Lead developer
- ViGenCell
01
Overview
VM-RHE-001 is a biologic drug candidate being developed by VivaMed BioPharma for the treatment of gout. It is currently in Phase 2 clinical development. Gout is a form of inflammatory arthritis caused by the accumulation of uric acid crystals in the joints, leading to sudden and severe pain. While the specific molecular target and mechanism of action for VM-RHE-001 have not been publicly disclosed by the developer, its classification as a biologic suggests it may target specific inflammatory cytokines or pathways involved in the body's immune response to urate crystals. The drug is a key component of VivaMed's rheumatology pipeline, which also includes treatments for osteoarthritis and fibromyalgia.
Beyond the preview
Go deeper on VM-RHE-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VM-RHE-001.